Jump Financial LLC Takes $261,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Jump Financial LLC acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,380 shares of the company’s stock, valued at approximately $261,000. Jump Financial LLC owned approximately 0.07% of Y-mAbs Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in YMAB. XTX Topco Ltd boosted its holdings in Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company’s stock worth $163,000 after buying an additional 9,468 shares in the last quarter. Barclays PLC boosted its holdings in Y-mAbs Therapeutics by 9.6% during the fourth quarter. Barclays PLC now owns 75,862 shares of the company’s stock worth $594,000 after buying an additional 6,640 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Y-mAbs Therapeutics by 371.7% during the fourth quarter. Renaissance Technologies LLC now owns 131,600 shares of the company’s stock worth $1,030,000 after buying an additional 103,700 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after buying an additional 6,131 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth approximately $253,000. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Price Performance

YMAB opened at $4.10 on Monday. The company has a market capitalization of $185.39 million, a PE ratio of -7.59 and a beta of 0.71. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $17.78. The business has a 50-day moving average of $4.87 and a 200-day moving average of $8.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the previous year, the business posted ($0.02) EPS. On average, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

YMAB has been the subject of a number of research reports. Truist Financial reduced their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Morgan Stanley cut their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. HC Wainwright reduced their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, March 21st. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Finally, Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $17.40.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 22.50% of the stock is owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.